DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0069779 A1 Tamarkin Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0069779 A1 Tamarkin Et Al US 20080069779A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0069779 A1 Tamarkin et al. (43) Pub. Date: Mar. 20, 2008 (54) FOAMABLE VEHICLE AND VITAMIN AND (60) Provisional application No. 60/843,140, filed on Sep. FLAVONOID PHARMACEUTICAL 8, 2006. Provisional application No. 60/784,793, filed COMPOSITIONS THEREOF on Mar. 21, 2006. Provisional application No. 60/679, 020, filed on May 9, 2005. Provisional application (75) Inventors: Dov Tamarkin, Maccabim (IL); Doron No. 60/530,015, filed on Dec. 16, 2003. Provisional Friedman, Karmei Yosef (IL); Meir application No. 60/492.385, filed on Aug. 4, 2003. Eini, Ness Ziona (IL); Tal Berman, Rishon LeZiyyon (IL); David Schuz, Publication Classification Moshav Gimzu (IL) (51) Int. Cl. Correspondence Address: A6IR 9/12 (2006.01) WILMERHALEABOSTON A6IP 37/00 (2006.01) 6O STATE STREET (52) U.S. Cl. ................................................................ 424/45 BOSTON, MA 02109 (US) (73) Assignee: Foamix Ltd., Ness Ziona (IL) (57) ABSTRACT (21) Appl. No.: 11/900,072 Vitamin and flavonoid containing compositions are provided (22) Filed: Sep. 10, 2007 that are stable to degradation. Stabilized compositions include one or more features including a hygroscopic Sol Related U.S. Application Data vent at a sufficient concentration to provide an Aw value of the hygroscopic Vitamin and or flavonoid containing com (63) Continuation-in-part of application No. 11/430,599, position of less than 0.9, antioxidant flavonoids that are filed on May 9, 2006, and which is a continuation preferentially oxidized before the vitamin, preservatives, in-part of application No. 10/835,505, filed on Apr. and hydrocarbon propellants selected to reduce the oxidation 28, 2004. potential of the composition. US 2008/0069779 A1 Mar. 20, 2008 FOAMABLE VEHICLE AND VITAMIN AND left following their topical application onto the skin, FLAVONOID PHARMACEUTICAL mucosal membranes and wounds. COMPOSITIONS THEREOF 0004 Foams and, in particular, foams that are substan CROSS REFERENCE TO RELATED tially based on non-aqueous solvents are complicated sys tems which do not form under all circumstances. Whilst APPLICATIONS aqueous foam formulations are better known, they are also 0001) This application claims the benefit under 35 U.S.C. complicated and similarly do not form under all circum S119(e) of U.S. Provisional Patent Application No. 60/843, StanceS. 140, filed on Sep. 8, 2006, and U.S. Provisional Patent Application No. TBA, filed on Sep. 4, 2007, each of which 0005 Antioxidants can be protective. Flavonoids are said is entitled "Foamable Vehicle and Vitamin Pharmaceutical to have high antioxidant activity and many health promoting Compositions Thereof.” This application is also a continu effects, including anti-inflammatory and anti-allergic effects ation-in-part application of co-pending U.S. patent applica as well as reducing the risk of cancer and pulmonary disease, tion Ser. No. 11/430,599 filed on May 9, 2006, which claims improved cardiovascular health and prevention of damage the benefit under 35 U.S.C. S 119(e) of U.S. Provisional from free radicals. The use of flavonoids for protecting Patent Application No. 60/679,020, filed on May 9, 2005, ascorbic acid and ascorbyl compounds has been proposed in entitled Hygroscopic Anti-Infective Compositions, and U.S. respect of lotions creams and gels Provisional Patent Application No. 60/784,793, filed on 0006 By using specialized delivery systems like micro Mar. 21, 2006, entitled Polyol Foamable Vehicle and Phar sponges it may be possible to incorporate hydrophobic maceutical Compositions Thereof, and which is also a active ingredients within the microSponges, which active continuation-in-part application of co-pending U.S. patent ingredients are released when the microSponges come into application Ser. No. 10/835,505, filed on Apr. 28, 2004, mechanical contact with the skin. which claims the benefit of priority under 35 U.S.C. S 119(e) to U.S. Provisional Patent Application No. 60/.530,015, filed SUMMARY on Dec. 16, 2003, and U.S. Provisional Patent Application 0007 Compositions containing vitamins and/or fla No. 60/492.385, filed on Aug. 4, 2003, all entitled “Oleagi vonoids or derivative thereof using non-aqueous and aque nous Pharmaceutical Foam; all of which are hereby incor ous carriers and foamable compositions containing them and porated in their entirety by reference. methods of treatment are described. 0008 Hygroscopic and aqueous stable vitamin contain BACKGROUND ing compositions and foamable therapeutic vitamin compo 0002 Vitamins are an essential component of the bodies sitions with and without additional active agents may be daily requirements and they are needed in various metabolic used for treatment of dermal and mucosal tissues are stable. pathways and to maintain good health. Some vitamins are They are non irritating, facilitate penetration at a target, are believed to support, facilitate, improve or optimize the presentable in an easily applicable stable form, can be function and effect of other vitamins and or active agents. handled with ease thereby facilitating compliance and either Compositions which can be applied to the skin, a body minimize or eliminate the amount of free water and in cavity, a mucosal Surface, the nose, the mouth, the eye, the consequence, the potential breakdown of vitamin by oxida ear canal, the respiratory system, the vagina and the rectum tion/hydrolysis, or provide an aqueous environment where that contain an effective amount of one or more vitamins they can resist or are protected from said potential break would be useful. Some vitamins are susceptible to oxidation down. and breakdown in Solution. Vitamins may for example 0009. In one or more embodiments, topical and body breakdown in the presence of water and may not be stable cavity foam formulations containing flavonoids on their own in compositions for Sufficiently long periods of time to and in combination with one or more vitamins are described. facilitate satisfactorily cosmetic and pharmaceutical uses. 0010. In one or more embodiments, topical and body Vitamin absorption is on the other hand also retarded by cavity foam formulations containing microSponges compris Substances like paraffin's and by certain pharmaceuticals. ing one or more active ingredients are provided. In particu 0003 External topical administration is an important lar, the microSponges comprise one or more vitamins or one route for the administration of drugs in disease treatment. or more flavonoids alone or in combination and also with Many groups of drugs, including, for example, antibiotic, other active ingredients. anti-fungal, anti-inflammatory, anesthetic, analgesic, anti allergic, corticosteroid, retinoid and anti-proliferative medi 0011. In other embodiments, the use of flavonoids on cations are preferably administered in hydrophobic media, their own, Synergistically, and in combination with other namely ointment. However, ointments often form an imper active agents is disclosed. meable barrier, so that metabolic products and excreta from 0012. In one or more aspects there is provided a hygro the wounds to which they are applied are not easily removed scopic Vitamin and or flavonoid containing composition or drained away. Furthermore, it is difficult for the active comprising: drug dissolved in the carrier to pass through the white petrolatum barrier layer into the wound tissue, so the effi 0013 a. at least one agent selected from the group cacy of the drug is reduced. In addition, ointments and consisting of Vitamins and flavonoids; creams often do not create an environment for promoting 0014) b. at least one hygroscopic solvent at a sufficient respiration of the wound tissue and it is not favorable to the concentration to provide an AW value of the hygroscopic normal respiration of the skin. An additional disadvantage of Vitamin and or flavonoid containing composition of less than petroleum jelly-based products relates to the greasy feeling 0.9; US 2008/0069779 A1 Mar. 20, 2008 0.015 c. a foam stabilizer selected from the group con 0.01% to about 5% by weight of at least one polymeric agent sisting of at least one surface-active agent; at least one selected from a bioadhesive agent, a gelling agent, a film polymeric agent selected from the group consisting of a forming agent and a phase change agent; and a Surface bioadhesive agent, a gelling agent, a film forming agent and active agent. a phase change agent and mixtures thereof, and 0033. In one or more embodiments, the hygroscopic 0016 d. a propellant at a concentration of about 3% to Substance is selected from the group consisting of polyeth about 25% by weight of the total composition, ylene glycols (PEGs), Surfactants comprising PEG, polyols, 0017 wherein the composition is contained in a pressur monosaccharides, disaccharides, oligosaccharides and Sugar ized container, is substantially flowable and provides a foam alcohols in an amount to provide hygroscopic properties, upon release. and honey. 0018. In one or more aspects there is provided a foamable 0034. In one or more embodiments there is provided a hygroscopic vitamin and or flavonoid containing composi foamable composition comprising a stabilized-vitamin, tion comprising: comprising: 0019 a. at least one agent selected from the group 0035) a water-unstable vitamin; consisting of Vitamins and flavonoids; 0036) an optional flavonoid; and 0020 b. at least one hygroscopic solvent at a sufficient 0037) a foamable carrier comprising: concentration to provide an AW value of the hygro 0038 i. water; Scopic Vitamin and or flavonoid containing composi 0039) ii. a foam stabilizer selected from the group tion of less than 0.9; consisting of at least one surface-active agent; at least 0021 c. a foam stabilizer selected from the group one polymeric agent selected from the group consisting consisting of at least one surface-active agent; and at of a bioadhesive agent, a gelling agent, a film forming least one polymeric agent selected from the group agent and a phase change agent and mixtures thereof; consisting of a bioadhesive agent, a gelling agent, a 0040 iii.
Load more

Recommended publications
  • Determination of the Major Flavonoid from Qina (Eucalyptus Globules L.) Using Shift Reagent, UV and IR Spectrophotometry
    Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam B.Sc. Science and Education, El-Zeim Alazhari University( 2003) Postgraduate Diploma in Applied Chemistry, Gezira University( 2009) A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Department of Applied Chemistry and Chemical Technology Faculty of Engineering and Technology Supervisor: Prof.Mohamed Abdel Karim Mohamed Co-supervisor:Dr. Mohamed Osman Babiker October -2012 ~1~ Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam Examination Committee: Name Position Signature Prof.Mohamed Abdel Karim Mohame Chairperson ................. Dr. Abo Bakr Khidir Ziada Intarnal Examiner …………. Dr. Abd Elsalam Abdalla Dafa Alla Extarnal Examiner …….. Date OF Examination: 6\10\2012 ~2~ Dedication This work is dedicated to My father who Deserved all respect, my mother For her care and passion, my husband for his help and support, my family and Friends. ~3~ Acknowledgements I thank Allah, Almighty for help. I wish to express my deep gratitude to my supervisor Prof. Mohamed Abdel Karim Mohamed for supervision and advice. I am grateful to all those who helped me to finish this thesis. My thanks are also extended to my colleagues for kind support. ~4~ Abstract Qina bark (Eucalyptus globules.L) is used in ethnomedicine as anti- inflammatory and antimalarial remedy.This study was aimed to extract and determine the physiochemical properties of the major flavonoid of quina bark. The plant material was collected from northern Kordofan and extracted with ethanol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Performance-Based Test Guideline for Stably Transfected Transactivation in Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists
    OECD/OCDE 455 Adopted: XXX OECD GUIDELINE FOR THE TESTING OF CHEMICALS Draft Performance-Based Test Guideline for Stably Transfected Transactivation In Vitro Assays to Detect Estrogen Receptor Agonists and Antagonists GENERAL INTRODUCTION Performance-Based Test Guideline 1. This Performance-Based Test Guideline (PBTG) describes the methodology of Stably Transfected Transactivation In Vitro Assays to detect Estrogen Receptor Agonists and Antagonists (ER TA assays). It comprises several mechanistically and functionally similar test methods for the identification of estrogen receptor (i.e, ER, and/or ER) agonists and antagonists and should facilitate the development of new similar or modified test methods in accordance with the principles for validation set forth in the OECD Guidance Document (GD) on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment (1). The fully validated reference test methods (Annex 2 and Annex 3) that provide the basis for this PBTG are: The Stably Transfected TA (STTA) assay (2) using the (h) ERα-HeLa-9903 cell line; and The BG1Luc ER TA assay (3) using the BG1Luc-4E2 cell line which predominately expresses hERα with some contribution from hER(4) (5). Performance standards (PS) (6) (7) are available to facilitate the development and validation of similar test methods for the same hazard endpoint and allow for timely amendment of this PBTG so that new similar test methods can be added to an updated PBTG; however, similar test methods will only be added after review and agreement that performance standards are met. The test methods included in this Test Guideline can be used indiscriminately to address countries’ requirements for test results on estrogen receptor transactivation while benefiting from the Mutual Acceptance of Data.
    [Show full text]
  • In Vitro Characterization of the Novel Solubilizing Excipient Soluplus
    In vitro characterization of the novel solubility enhancing excipient Soluplus⃝R DISSERTATION zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Michael Linn Saarbrücken 2011 Tag des Kolloquiums: 19. Dezember 2011 Dekan: Prof. Dr. Wilhelm F. Maier Berichterstatter: Prof. Dr. Claus-Michael Lehr Prof. Dr. Rolf Hartmann Vorsitz: Prof. Dr. Ingolf Bernhardt Akad. Mitarbeiter: Dr. Matthias Engel To my offspring The important thing is not to stop questioning. Curiosity has its own reason for existing. Albert Einstein Table of Contents Table of Contents 1. Short summary V 2. Kurzzusammenfassung VII 3. General Introduction 1 3.1. Liberation and absorption of drugs after oral application ........... 1 3.1.1. Drug solubility and dissolution ...................... 2 3.1.2. Principles of drug absorption across the intestinal mucosa ..... 4 3.2. Formulation of poorly aqueous soluble drugs by micellar solubilization .. 10 3.3. Solid dispersions and hot melt extrusion ..................... 14 3.3.1. Solid dispersions for pharmaceutical applications ........... 14 3.3.2. Hot melt extrusion ............................. 15 3.4. The novel solubility enhancer Soluplus⃝R ..................... 18 3.5. The Caco-2 cell culture model ........................... 19 3.6. Aims of this thesis .................................. 21 3.6.1. The Caco-2 model as predictive tool for Soluplus⃝R formulations .. 22 3.6.2. Potential inhibition of P-glycoprotein and/or trypsin by Soluplus⃝R . 23 3.6.3. Optimization of Soluplus⃝R formulations ................ 23 4. Soluplus⃝R as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo 25 4.1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez Et Al
    US 20140302163A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0302163 A1 Sanchez et al. (43) Pub. Date: Oct. 9, 2014 (54) WATER WITH IMPROVED TRANSDERMAL A613 L/714 (2006.01) AND CELLULAR DELIVERY PROPERTIES A 6LX3/59 (2006.01) AND METHODS OF MANUFACTURE AND A 6LX3/593 (2006.01) USE THEREOF A2.3L 2/52 (2006.01) A63/94 (2006.01) (71) Applicant: Subtech Industries, LLC, Stuart, FL (52) U.S. Cl. (US) CPC. A23L I/293 (2013.01); A23L 2/52 (2013.01); C02F I/30 (2013.01); A61 K33/00 (2013.01); (72) Inventors: David Sanchez, Port Saint Lucie, FL A6 IK3I/194 (2013.01); A61 K3I/714 (US); Len Deweerdt, Port Saint Lucie, (2013.01); A61 K3I/519 (2013.01); A61 K FL (US) 31/593 (2013.01); A61K 36/02 (2013.01) USPC ................. 424/600; 426/2: 426/66; 210/251: (73) Assignee: Subtech Industries, LLC, Stuart, FL 210/198.1; 210/201; 210/202: 514/569; 514/52: (US) 424/195.17; 514/789 (21) Appl. No.: 14/214,945 (57) ABSTRACT 1-1. A process for preparing conventional water sources for pro (22) Filed: Mar 16, 2014 viding “ideal state' cellular wellness benefits via topical Related U.S. Application Data hydrationabsorption. and The natural invention’s transdermal, process considersepithelial preconditioned O epicellular (60) Provisional application No. 61/788,206, filed on Mar. water sources that have removed solids, dissolved solids, 15, 2013. contaminants—both organic and inorganic and Subsequently the method purifies the water respective of removing patho Publication Classification gens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal (51) Int.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Nutraceutical Potential of Carica Papaya in Metabolic Syndrome
    nutrients Review Nutraceutical Potential of Carica papaya in Metabolic Syndrome Lidiani F. Santana 1, Aline C. Inada 1 , Bruna Larissa Spontoni do Espirito Santo 1, Wander F. O. Filiú 2, Arnildo Pott 3, Flávio M. Alves 3 , Rita de Cássia A. Guimarães 1, Karine de Cássia Freitas 1,* and Priscila A. Hiane 1 1 Graduate Program in Health and Development in the Central-West Region of Brazil, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil 2 Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil 3 Institute of Biosciences, Federal University of Mato Grosso do Sul-UFMS, MS 79079-900 Campo Grande, Brazil * Correspondence: [email protected]; Tel.: +55-67-3345-7445 Received: 21 June 2019; Accepted: 10 July 2019; Published: 16 July 2019 Abstract: Carica papaya L. is a well-known fruit worldwide, and its highest production occurs in tropical and subtropical regions. The pulp contains vitamins A, C, and E, B complex vitamins, such as pantothenic acid and folate, and minerals, such as magnesium and potassium, as well as food fibers. Phenolic compounds, such as benzyl isothiocyanate, glucosinolates, tocopherols (α and δ), β-cryptoxanthin, β-carotene and carotenoids, are found in the seeds. The oil extracted from the seed principally presents oleic fatty acid followed by palmitic, linoleic and stearic acids, whereas the leaves have high contents of food fibers and polyphenolic compounds, flavonoids, saponins, pro-anthocyanins, tocopherol, and benzyl isothiocyanate. Studies demonstrated that the nutrients present in its composition have beneficial effects on the cardiovascular system, protecting it against cardiovascular illnesses and preventing harm caused by free radicals.
    [Show full text]
  • (Lichtenstein, Ebmeyer Et Al
    Electronic Supplementary Material (ESI) for Food & Function. This journal is © The Royal Society of Chemistry 2015 Supplementary Data Relevant pH and lipase for in vitro models of gastric digestion Laura Samsa,b, Julie Paume b, Jacqueline Giallo b and Frédéric Carrièrea* a CNRS, Aix Marseille Université, Enzymologie Interfaciale et Physiologie de la Lipolyse UMR7282, 31 Chemin Joseph Aiguier, 13402 Marseille Cedex 20, France b GERME S.A., Technopôle Marseille Provence Château-Gombert, ZAC la Baronne,12 Rue Marc Donadille, 13013 Marseille List of the 340 articles with “in vitro digestion” in their title, used for statistics on in vitro digestion models: Aarak, K., B. Kirkhus, et al. (2013). "Release of EPA and DHA from salmon oil–a comparison of in vitro digestion with human and porcine gastrointestinal enzymes." British Journal of Nutrition 110(08): 1402-1410. Aarak, K. E., B. Kirkhus, et al. (2014). "Effect of broccoli phytochemical extract on release of fatty acids from salmon muscle and salmon oil during in vitro digestion." Food & function 5(9): 2331-2337. Aarak, K. E., N. M. Rigby, et al. (2013). "The impact of meal composition on the release of fatty acids from salmon during in vitro gastrointestinal digestion." Food & function 4(12): 1819-1826. Abdalla, A., S. Klein, et al. (2008). "A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: characterization, dissolution, in vitro digestion and incorporation into solid pellets." European Journal of Pharmaceutical Sciences 35(5): 457-464. Aditya, N., M. Shim, et al. (2013). "Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity." Journal of agricultural and food chemistry 61(8): 1878-1883.
    [Show full text]
  • WO 2014/145352 Al 18 September 2014 (18.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/145352 Al 18 September 2014 (18.09.2014) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C02F 3/06 (2006.01) C02F 9/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C02F 9/08 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (21) International Application Number: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, PCT/US20 14/030094 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (22) International Filing Date: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, 16 March 2014 (16.03.2014) TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 61/788,206 15 March 2013 (15.03.2013) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: SUBTECH INDUSTRIES LLC [FJ/US]; PO EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Box 1226, Stuart, FL 34995 (US).
    [Show full text]
  • Cumulative Cross Index to Iarc Monographs
    PERSONAL HABITS AND INDOOR COMBUSTIONS volume 100 e A review of humAn cArcinogens This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 29 September-6 October 2009 LYON, FRANCE - 2012 iArc monogrAphs on the evAluAtion of cArcinogenic risks to humAns CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS The volume, page and year of publication are given. References to corrigenda are given in parentheses. A A-α-C .............................................................40, 245 (1986); Suppl. 7, 56 (1987) Acenaphthene ........................................................................92, 35 (2010) Acepyrene ............................................................................92, 35 (2010) Acetaldehyde ........................36, 101 (1985) (corr. 42, 263); Suppl. 7, 77 (1987); 71, 319 (1999) Acetaldehyde associated with the consumption of alcoholic beverages ..............100E, 377 (2012) Acetaldehyde formylmethylhydrazone (see Gyromitrin) Acetamide .................................... 7, 197 (1974); Suppl. 7, 56, 389 (1987); 71, 1211 (1999) Acetaminophen (see Paracetamol) Aciclovir ..............................................................................76, 47 (2000) Acid mists (see Sulfuric acid and other strong inorganic acids, occupational exposures to mists and vapours from) Acridine orange ...................................................16, 145 (1978); Suppl. 7, 56 (1987) Acriflavinium chloride ..............................................13,
    [Show full text]